PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
Studying Carcinoma of esophagus
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- University of Aarhus
- Principal Investigator
- Marianne Nordsmark, Dr.University of Aarhus
- Intervention
- Photon Radiotherapy(radiation)
- Enrollment
- 396 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2032
Study locations (15)
- Catholic University of Leuven, Leuven, Belgium
- Aarhus University Hospital (AUH), Aarhus, Denmark
- Centre Léon Bérard (CLB), Lyon, France
- Centre Antoine Lacassagne (CAL), Nice, France
- Institut Curie, Paris, France
- Technische Universität Dresden (TUD), Dresden, Germany
- San Raffaele Hospital, Milan, Italy
- Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy
- Azienda Provinciale Per I Servizi Sanitari (APSS), Trento, Italy
- Academisch Ziekenhuis Groningen (UMCG), Groningen, Netherlands
- Stichting Maastricht Radiation Oncology (MAASTRO), Maastricht, Netherlands
- Paul Scherrer Institute (PSI), Villigen, Switzerland
- University Hospital Zurich (USZ), Zurich, Switzerland
- University College London Hospital (UCLH), London, United Kingdom
- The Christie NHS foundation trust, Manchester, United Kingdom
Collaborators
University of Leeds · KU Leuven · University College, London · Aarhus University Hospital · Technische Universität Dresden · Academisch Ziekenhuis Groningen · CNAO National Center of Oncological Hadrontherapy · Agenzia Nazionale per i Servizi Sanitari Regionali · Centre Antoine Lacassagne · Centre Leon Berard · Institut Curie · Maastro Clinic, The Netherlands · University College London Hospitals · The Christie NHS Foundation Trust · Paul Scherrer Institut, Center for Proton Therapy · HollandPTC · IBA worldwide · Varian- A Siemens Healthineer Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05055648 on ClinicalTrials.govOther trials for Carcinoma of esophagus
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06990178Adaptive Neoadjuvant Therapy for Esophageal CancerCancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- RECRUITINGNCT07464470Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal CancersBlokhin's Russian Cancer Research Center
- RECRUITINGNANCT07307560High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea PatientsZhejiang University
- ENROLLING BY INVITATIONEARLY PHASE1NCT07371247Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and EfficacyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07217704Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.SOFIE
- ACTIVE NOT RECRUITINGPHASE2NCT07339488Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell CarcinomaChuangzhen Chen
- RECRUITINGPHASE2NCT07205731Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell CarcinomaUniversity Hospital, Clermont-Ferrand
- RECRUITINGPHASE2NCT07071103Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid TumorsChuangzhen Chen